Treatment Of Opioid Use Disorder Among Commercially Insured US Adults, 2008-17

被引:20
作者
Shen, Karen [1 ]
Barrette, Eric [2 ]
Dafny, Leemore S. [3 ,4 ]
机构
[1] Harvard Univ, Econ, Cambridge, MA 02138 USA
[2] Medtronic, Hlth Econ, Washington, DC USA
[3] Harvard Sch Business, Business Adm, Boston, MA 02163 USA
[4] Harvard Univ, John F Kennedy Sch Govt, Cambridge, MA 02138 USA
关键词
D O I
10.1377/hlthaff.2019.01041
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
There is abundant literature on efforts to reduce opioid prescriptions and misuse, but comparatively little on the treatment provided to people with opioid use disorder (OUD). Using claims data representing 12-15 million nonelderly adults covered through commercial group insurance during the period 2008-17, we explored rates of OUD diagnoses, treatment patterns, and spending. We found three key patterns; The rate of diagnosed OUD nearly doubled during 2008-17, and the distribution has shifted toward older age groups; the likelihood that diagnosed patients will receive any treatment has declined, particularly among those ages forty-five and older, because of a reduction in the use of medication-assisted treatment (MAT) and despite clinical evidence demonstrating its efficacy; and treatment spending is lower for patients who choose MAT. These patterns suggest that policies supporting the use of MAT are critical to addressing the undertreatment of OUD among the commercially insured and that further research to assess the cost-effectiveness of treatment with versus without medication is needed.
引用
收藏
页码:993 / 1001
页数:9
相关论文
共 16 条
[1]  
American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI 10.1176/appi.books.9780890425596
[2]  
[Anonymous], KEY SUBST US MENT HL
[3]   Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians [J].
Arfken, Cynthia L. ;
Johanson, Chris-Ellyn ;
di Menza, Salvatore ;
Schuster, Charles Roberts .
JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2010, 39 (02) :96-104
[4]  
Authors calculations from Substance Abuse and Mental Health Services Administration, 2020, PRACT PROGR DAT
[5]  
Clemans-Cope Lisa., 2019, State variation in Medicaid prescriptions for opioid use disorder from 2011 to 2018". In
[6]  
Ginder-Vogel K., 2019, PHARMACISTS TAKE SUB
[7]  
Henry J., 2018, HLTH INS COV AD 19 6
[8]  
IMS Institute for Healthcare Informatics, 2016, US OP REC MED REC EV
[9]   Prevalence of DSM-IV and DSM-5 alcohol, cocaine, opioid, and cannabis use disorders in a largely substance dependent sample [J].
Peer, Kyle ;
Rennert, Lior ;
Lynch, Kevin G. ;
Farrer, Lindsay ;
Gelernter, Joel ;
Kranzler, Henry R. .
DRUG AND ALCOHOL DEPENDENCE, 2013, 127 (1-3) :215-219
[10]   Buprenorphine Use and Spending for Opioid Use Disorder Treatment: Trends From 2003 to 2015 [J].
Roberts, Andrew W. ;
Saloner, Brendan ;
Dusetzina, Stacie B. .
PSYCHIATRIC SERVICES, 2018, 69 (07) :832-835